Marketing: Page 54
-
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
The FDA's approval of Harvoni and Sovaldi in patients 12 and older is the latest example.
By Jacob Bell • April 12, 2017 -
Neurocrine's Ingrezza secures FDA approval
The company's stock jumped more than 20% after the FDA approved the tardive dyskinesia drug — Neurocrine's first product cleared for market.
By Jacob Bell • April 12, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Sponsored by ZS Associates
What pharma needs to know about local healthcare markets
Aligning customer engagement teams to local healthcare markets could enable pharmaceutical reps and account managers to deliver better value to patients.
By Paul Darling • April 11, 2017 -
In familiar routine, ICER finds rheumatoid arthritis drugs overpriced
The research group has come under fire from the industry for its cost-effectiveness calculations, which have found many top brands to be too expensive.
By Ned Pagliarulo • April 10, 2017 -
Deep Dive
The orphan drug dilemma: How to price for a tiny market
Despite small patient populations and historically high prices, the pricing model for rare disease drugs has reached a turning point, prompting companies and insurers to push for new innovative models.
By Lisa LaMotta • April 10, 2017 -
Novartis licenses bite-sized biotech's dry eye drug
The deal with Lubris Biotech adds another candidate to Novartis ophthalmology pipeline, which may help the company's struggling eye care business down the line.
By Jacob Bell • April 7, 2017 -
PhRMA takes shot at payers in drug pricing war
A new print and digital ad campaign dubbed "Share the Savings" suggests insurers aren't passing along the discounts they receive from drugmakers.
By Ned Pagliarulo • April 6, 2017 -
Sanofi pays $20M bill to resolve claims of overcharging
The French pharma's vaccines arm will shell out to resolve claims it overcharged the VA between 2002 and 2011.
By Suzanne Elvidge • April 5, 2017 -
Should the US government license hep C drugs?
The National Academies of Sciences, Engineering and Medicine is looking at innovative payment models to address ways to treat all patients with hepatitis C, while not depriving pharmaceutical companies of sales.
By Suzanne Elvidge • March 31, 2017 -
Drug prices continue to climb, but who's to blame?
A new report released by the powerful industry trade group PhRMA says payers are failing to pass on savings to consumers from drugmaker discounts.
By Ned Pagliarulo , Suzanne Elvidge • March 30, 2017 -
Legwork leaves Sanofi, Regeneron confident in Dupixent uptake
The companies are optimistic about the prospects of their eczema drug Dupixent, which has a list price of $37,000 per year, getting on payer formularies.
By Jacob Bell • March 29, 2017 -
Sanofi, Regeneron's eczema drug Dupixent gains FDA approval
The highly-anticipated Dupixent is expected to rake in around $3 billion in peak annual sales, according to some industry followers.
By Jacob Bell • March 28, 2017 -
Courtesy of AbbVie
JAMA confirms DTC drove 'Low-T' craze
A recent report shows the strength of DTC advertising and how it can be abused.
By Lisa LaMotta • March 23, 2017 -
J&J, GSK pull ads from YouTube amid display concerns
A growing list of major corporations have paused advertising on the media channel due to alarm that product marketing may be appearing next to offensive material.
By Ned Pagliarulo • March 23, 2017 -
Newron finally secures US approval for Parkinson's drug
Xadago has been approved in the EU since early 2015, but troubles with the FDA had kept it off the U.S. market until now.
By Suzanne Elvidge • March 22, 2017 -
Lilly offers up drug pricing details amid ongoing scrutiny of industry
Following criticism over the cost of its insulin drugs, the company gave a glimpse into its pricing decisions in an annual report.
By Jacob Bell • March 20, 2017 -
FDA advisory panel votes against Endo's opioid painkiller
After the panel concluded the risks associated with Opana ER outweigh its benefits, the FDA will now have to decide what reforms to take for the prescription opioid.
By Jacob Bell • March 15, 2017 -
OncBioMune, EOC aim to develop gastric cancer drug
The commercialization deal is part of the Louisiana-based biopharma’s push southward into Mexico, Central America and South America.
By Judy Packer-Tursman • March 15, 2017 -
Bernie Sanders calls for more broadcast news on drug pricing
The Vermont senator sent a letter to Fox News, CNN and four other television news networks criticizing their lack of coverage on pharmaceutical pricing.
By Jacob Bell • March 15, 2017 -
Acorda taps Amazon's Alexa to build MS awareness
Say "Alexa, start MS Awareness," and Amazon's voice recognition software will deliver facts and tips about multiple sclerosis from Acorda's app.
By Suzanne Elvidge • March 15, 2017 -
Mylan clears way for biosimilar Herceptin launch in US
The EpiPen manufacturer reached a settlement deal with Roche, granting Mylan a license to commercialize what could be the first Herceptin copy in the U.S.
By Ned Pagliarulo • March 13, 2017 -
Using social to tap into the rare disease market
The annual Rare Disease Day is designed to connect the rare disease community, build awareness and raise research funds.
By Judy Packer-Tursman • March 10, 2017 -
5 biotech CEOs on payers, investors and big bets
BioPharma Dive sat down with the top executives from several biotechs at the BIO CEO conference in New York. Here is what they had to say about the challenges they face, dealing with payers and educating investors.
By Lisa LaMotta • March 9, 2017 -
Express Scripts challenges Gilead in pricing blame game
The pharmacy benefit manager fired back at Gilead, calling on the drugmaker to lower the costs of its hepatitis C medicines and reimburse payers.
By Lisa LaMotta • March 8, 2017 -
MS drugs too expensive, ICER says
A new report from the Institute for Clinical and Economic Review found only Sanofi's Lemtrada met its cost-effectiveness benchmark.
By Ned Pagliarulo • March 7, 2017
Previous
